Literature DB >> 9624490

Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.

O Kozawa1, T Uematsu, H Matsuno, M Niwa, Y Takiguchi, S Matsumoto, M Minamoto, Y Niida, M Yokokawa, S Nagashima, M Kanamaru.   

Abstract

The pharmacokinetics and tolerability of a new parenteral carbapenem antibiotic, biapenem (L-627), were studied in healthy elderly volunteers aged 65 to 74 years (71.6 +/- 2.7 years [mean +/- standard deviation], n = 5; group B) and > or = 75 years (77.8 +/- 1.9 years, n = 5; group C), following single intravenous doses (300 and 600 mg), and compared with those of healthy young male volunteers aged 20 to 29 years (23.0 +/- 3.5 years, n = 5; group A). The agent was well tolerated in all three age groups. Serial blood and urine samples were analyzed for biapenem to obtain key pharmacokinetic parameters by both two-compartment model-dependent and -independent methods. The maximum plasma concentration and area under plasma concentration-versus-time curve (AUC) increased in proportion to the dose in all three groups. Statistically significant age-related effects for AUC, total body clearance, and renal clearance (CLR) were found, while elimination half-life (t1/2 beta) and percent cumulative recovery from urine of unchanged drug (% UR) remained unaltered (t1/2 beta, 1.51 +/- 0.42 [300 mg] and 2.19 +/- 0.64 [600 mg] h [group A], 1.82 +/- 1.14 and 1.45 +/- 0.36 h [group B], and 1.75 +/- 0.23 and 1.59 +/- 0.18 h [group C]; % UR, 52.6% +/- 3.0% [300 mg] and 53.1% +/- 5.1% [600 mg] [group A], 46.7% +/- 7.4% and 53.0% +/- 4.8% [group B], and 50.1% +/- 5.2% and 47.1% +/- 7.6% [group C]). A significant linear correlation was observed between the CLR of biapenem and creatinine clearance at the dose of 300 mg but not at 600 mg. The steady-state volume of distribution tended to be decreased with age, although not significantly. Therefore, the age-related changes in parameters of biapenem described above were attributable to the combination of decreased lean body mass and lowered renal function of the elderly subjects. However, the magnitude of those changes does not necessitate dosage adjustment in elderly patients with normal renal function for their age.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624490      PMCID: PMC105618     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Effects of age and gender on pharmacokinetics of cefepime.

Authors:  R H Barbhaiya; C A Knupp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.

Authors:  K Ubukata; M Hikida; M Yoshida; K Nishiki; Y Furukawa; K Tashiro; M Konno; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic.

Authors:  M Hikida; K Kawashima; K Nishiki; Y Furukawa; K Nishizawa; I Saito; S Kuwao
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 4.  Principles of drug therapy in geriatric patients.

Authors:  R W Sloan
Journal:  Am Fam Physician       Date:  1992-06       Impact factor: 3.292

5.  Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.

Authors:  O Kozawa; T Uematsu; H Matsuno; M Niwa; S Nagashima; M Kanamaru
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  Adult lean body mass declines with age: some longitudinal observations.

Authors:  G B Forbes; J C Reina
Journal:  Metabolism       Date:  1970-09       Impact factor: 8.694

Review 7.  The need for pharmacokinetics protocols in special cases.

Authors:  M B Regazzi; R Rondanelli; M Calvi
Journal:  Pharmacol Res       Date:  1993 Jan-Feb       Impact factor: 7.658

Review 8.  Pharmacokinetic studies in elderly people. Are they necessary?

Authors:  P Crome; R J Flanagan
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

9.  Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic.

Authors:  M Nakashima; T Uematsu; K Ueno; S Nagashima; H Inaba; M Nakano; K Kosuge; M Kitamura; T Sasaki
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1993-02

Review 10.  Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

Authors:  B R Meyers; P Wilkinson
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

View more
  4 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Biapenem.

Authors:  Caroline M Perry; Tim Ibbotson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Structure of apo- and monometalated forms of NDM-1--a highly potent carbapenem-hydrolyzing metallo-β-lactamase.

Authors:  Youngchang Kim; Christine Tesar; Joseph Mire; Robert Jedrzejczak; Andrew Binkowski; Gyorgy Babnigg; James Sacchettini; Andrzej Joachimiak
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.